Literature DB >> 16525177

Physiologic and metabolic magnetic resonance imaging in gliomas.

Yue Cao1, Pia C Sundgren, Christina I Tsien, Thomas T Chenevert, Larry Junck.   

Abstract

Magnetic resonance (MR) imaging provides excellent soft tissue differentiation and in vivo assessment of physiologic and metabolic properties of tissue. As new and more aggressive treatment modalities and combined modalities are being investigated for brain tumor treatment, it is becoming more important to accurately define tumor volumes for treatment planning, to determine the most aggressive tumor regions for intensified radiation treatment, to identify early regional response to therapy for reoptimization of treatment, and to detect early indicators of developing normal tissue toxicity. Readily available MR techniques of physiologic and metabolic imaging can currently provide useful information regarding tumor tissue properties including chemical composition, cerebral blood volume, perfusion, vascular permeability, and water mobility. This article will focus on the potential value of MR physiologic and metabolic imaging in the clinical management of malignant gliomas.

Entities:  

Mesh:

Year:  2006        PMID: 16525177     DOI: 10.1200/JCO.2005.04.7233

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  40 in total

1.  Imaging Advances in Stereotactic Radiosurgery.

Authors:  Christina Tsien; Robert E Drzymala; Keith Rich
Journal:  Mo Med       Date:  2015 Sep-Oct

2.  Scaling of number, size, and metabolic rate of cells with body size in mammals.

Authors:  Van M Savage; Andrew P Allen; James H Brown; James F Gillooly; Alexander B Herman; William H Woodruff; Geoffrey B West
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-01       Impact factor: 11.205

Review 3.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Authors:  Alba A Brandes; Alicia Tosoni; Federica Spagnolli; Giampiero Frezza; Marco Leonardi; Fabio Calbucci; Enrico Franceschi
Journal:  Neuro Oncol       Date:  2008-04-09       Impact factor: 12.300

4.  Preclinical MRI: Studies of the irradiated brain.

Authors:  Joel R Garbow; Christina I Tsien; Scott C Beeman
Journal:  J Magn Reson       Date:  2018-04-26       Impact factor: 2.229

5.  Tumor image signatures and habitats: a processing pipeline of multimodality metabolic and physiological images.

Authors:  Daekeun You; Michelle M Kim; Madhava P Aryal; Hemant Parmar; Morand Piert; Theodore S Lawrence; Yue Cao
Journal:  J Med Imaging (Bellingham)       Date:  2017-11-15

Review 6.  The promise of dynamic contrast-enhanced imaging in radiation therapy.

Authors:  Yue Cao
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

Review 7.  MR-guided radiation therapy: transformative technology and its role in the central nervous system.

Authors:  Yue Cao; Chia-Lin Tseng; James M Balter; Feifei Teng; Hemant A Parmar; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

8.  Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.

Authors:  Christina Tsien; Craig J Galbán; Thomas L Chenevert; Timothy D Johnson; Daniel A Hamstra; Pia C Sundgren; Larry Junck; Charles R Meyer; Alnawaz Rehemtulla; Theodore Lawrence; Brian D Ross
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

Review 9.  Biology, genetics and imaging of glial cell tumours.

Authors:  C Walker; A Baborie; D Crooks; S Wilkins; M D Jenkinson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

10.  Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas.

Authors:  Remy Guillevin; Carole Menuel; Hugues Duffau; Michel Kujas; Laurent Capelle; Agnès Aubert; Sophie Taillibert; Ahmed Idbaih; Joan Pallud; Giovanni Demarco; Robert Costalat; Khê Hoang-Xuan; Jacques Chiras; Jean-Noel Vallée
Journal:  J Neurooncol       Date:  2007-12-28       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.